Awet’s Pearls of Wisdom
It is anticipated that the longevity market will surpass the existing health care market in the long run.
As a result, it provides investors with unique opportunities to invest in the longevity space.
A key part of the YFS Intelligent Wealth Fund’s investment strategy is to invest in companies that have huge market potential and pipelines that are contributing to human longevity by making a meaningful impact on our society.
The fund seeks to benefit from companies that are enhancing our quality of life using new innovative technology and a wide range of anti-ageing therapies that are expected to have the potential to extend human life.
Gene editing and artificial intelligence have transformed the healthcare sector, offering companies and investors a unique opportunity to develop therapeutics, services, and technologies related to ageing.
Modern scientific capability has profoundly altered the course of human life. People live longer and better than at any other time in history.
In the biodata revolution, wearable, constantly connected technologies will collect information about our health, such as our eating habits and exercise, which can be used to help us become healthier.
It is expected that the cost of life-extending therapies will decline as treatments become more widespread and generic forms of drugs become available.
How long will people live in the future? Global life expectancy is 70 years for men, and 75 years for women.
By 2050, the World Economic Forum predicts nearly 3.7 million people will be living to 100 and older, up from just 95,000 in 1990.
Ray Kurzweil described ageing as a solvable engineering problem that could ultimately extend human lifespans indefinitely.
In addition, he said we may be able to add one year to our life span each year relatively soon.
Research shows that effectively slowing the typical ageing process could contribute $38 trillion in value in a year of added life expectancy and $367 trillion in ten years.
There will be one in six people over 60 in the world by 2030. By 2050, however, the world’s over-60 population will double to 2.1 billion. In other words, this indicates the potential size of the total addressable market.
Investing in longevity has been growing rapidly due to the growing interest from investors, life sciences and health care communities, government agencies, and health tech companies to solve the underlying issue of diseases and ageing, which will ultimately lead to a longer, healthier and happier life for humanity.
For example, the founder of Amazon Jeff Bezos invested in Altos Labs. Altos Labs is pursuing biological reprogramming technology, a way to rejuvenate cells in the lab that some scientists think could be extended to revitalise entire animal bodies, ultimately prolonging human life.
Slowing the ageing process is not just possible but inevitable. One of our companies Juvenescence has launched a commercial product, a drinkable ketone ester called Metabolic Switch, which will help the body reach ketosis which normally requires extreme dieting. It will put you into ketosis without requiring you to fast for three days or more.
Furthermore, Juvenescence is diversified across 21 projects, which provides margin of safety. One example investment in LyGenesis, Inc. is a clinical-stage cell therapy company that transforms a patient’s lymph nodes into bioreactors capable of growing functioning ectopic organs and many more projects.
We are on the verge of a lifespan revolution. Within the next decade, life expectancy will rise to between 110 and 120 years. Our fund, the YFS Intelligent Wealth Fund is well invested to capitalise on the opportunities that will make us live longer and healthier because ageing affects everyone, everywhere.
This blog is written by Awet Ghirmay. He is a Head of Investment Research at Minerva Money Management Limited.
The Fund is authorised in the United Kingdom and regulated by the Financial Conduct Authority (FCA) Firm Reference Number:754570.
Risk warnings
*The value of investments and the income derived from them may fall as well as rise. You may not get back what you invest. This communication is for general information only and is not intended to be individual advice. You are recommended to seek competent professional advice before taking any action. All statements concerning the tax treatment of products and their benefits are based on our understanding of current tax law and HM Revenue and Customs practice. Levels and bases of tax relief are subject to change. This blog is based on my own observations and opinions.
